Nine antigen systems were defined. Two were
By using conventional heteroantisera, the cell surface antigens of erythrocyte rosette-negative (E-),. surface immunoglobulinnegative (sIg-) acute lymphocytic leukemia (null-ALL) have been studied in considerable detail. (1) (2) (3) (4) (5) . One ofthe best characterized antigens of null-ALL is the common ALL antigen (cALL) (6) , which was first reported to be present only in null-ALL and chronic myelocytic leukemia in blastic crisis (CML-BC) but was later shown to be also expressed by a small fraction offetal liver and regenerating bone marrow cells (7) . Biochemical characterization of the cALL showed it to be a Mr 100,000 glycoprotein (gpl00) (8) . Several other laboratories have also detected gpl00 antigens on ALL cells with similar serological characteristics (3, 9, 10) .
In the present study, monoclonal antibodies were developed against null-ALL cells obtained from a single patient, and nine distinct antigen systems were defined. Among these, the NL- 22 antigen is restricted to null-ALL and the NL-1 antigen closely resembles cALL. Surface antigenic profiles of leukemia cells from 16 cases ofnull-ALL were studied by using this panel of monoclonal antibodies.
MATERIALS AND METHODS
Leukemia and Lymphoid Cells. Peripheral blood or bone marrow aspirates obtained from patients with leukemia or normal volunteers were separated by Ficoll/Paque (Pharmacia) density sedimentation ('11) , and interface layers were collected.
Aliquots of the cell suspensions were cryopreserved in liquid nitrogen. Specimens of lymphoid tissues (tonsil, spleen, and fetal thymus) were placed in RPMI-1640 (GIBCO) containing 10% (vol/vol) fetal bovine serum (Microbiological Associates, Walkersville, MD). Single-cell suspensions were obtained by gentle manual squeezing of tissue specimens in sterile vinyl bags.
Cell surface markers-surface immunoglobulin (sIg), sheep erythrocyte rosettes (E), erythrocyte-antibody-complement rosettes (EAC), and erythrocyte-antibody rosettes (EA)-were determined by K. Koike and T. Suchi of this institution, according to the method of Tachibana and Ishikawa (12) .
Cultured Cell Lines. Cultured cell lines derived from hematopoietic tumors and other malignancies are listed in Table  1 (see refs. [13] [14] [15] [16] . Cultures were maintained in RPMI-1640 supplemented with streptomycin (100 :.g/ml), penicillin (100 units/ml), 2 mM glutamine and 10% fetal bovine serum.
Serological Procedure. Immune adherence assays and qualitative absorption tests were performed as described (15, 16 (21) described a monoclonal antibody (J-5) that appeared to be specific for cALL originally defined by Greaves with conventional heteroantibody. J-5 antibody was initially reported to react only with NALM-1 and LAZ-222 null-ALL cell lines, but subsequent studies showed Proc. Natl Acad. Sci. USA 79 (1982) 4389 antibody confirmed that null-ALL was the only cell type that expressed the NL-22 antigen. Kersey recently described a monoclonal antibody (BA-2) produced against a NALM-6 cell lines that identifies a Mr 24,000 protein present on null-ALL and B-CLL cells (24) . A monoclonal antibody (PI 153/3) produced against a neuroblastoma cell line by Kennett and Gilbert (25) was also reported to react against null-ALL, B-CLL, and CML-BC (Iymphoid type) (26 (27) also reported the presence of at least five patterns of reactivity by studying surface antigens of T-ALL with an extensive panel ofmonoclonal antibodies. These findings are con- 
